The invention mainly relates to a method for preparing compound amino acid injection liquid ( 20AA ) , and belongs to the technical field of medicines .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The problems that the amino acid is oxidized and degraded and solution color is deepened because the solution is in contact with oxygen for a long time during preparation and filling are solved by vacuumizing and filling nitrogen during preparation of the injection liquid .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
In the method , the injection liquid is dissolved in batch or in several times according to the dissolution difficulty of amino acid , so that the problem that the indissolvable amino acid crystal separates out during preparation is solved , and the stability and the quality of the amino acid injection liquid are guaranteed to the maximum limit .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The method has the advantages of simple operation , scientific and reasonable process , low cost and low requirement on production equipment .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention provides a sweetener wherein corosolic acid , and at least one selected from the group consisiting of a sucrase inhibitor and indigestible dextrin , are added to sucrose .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention consists of a compound that can be represented by general formula ( 1 ) or a pharmacologically permitted salt thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
( 1 ) ( In the formula , R1 , R2 , R3 , and R4 are as defined in the claims . )
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed is an antitumor agent which contains , as an active ingredient , a thalidomide derivative selected from the compounds shown below .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to new piperidine derivatives of the formula ( I ) to their use as medicaments , to methods for their therapeutic use and to pharmaceutical compositions containing them .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
This invention is directed to an oral modified release formulation of the phytoestrogen 8-Prenylnaringenin and its use for the treatment of symptoms of estrogen deficiency .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Provided is a pharmaceutical composition comprising rosuvastatin or a pharmaceutically acceptable salt thereof and an anhydrous dibasic calcium phosphate as a stabilizer .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The composition of the present invention has outstanding storage stability .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention provides a pharmaceutical composition for relaxing bowels and purging intestines , wherein the pharmaceutical composition comprises polyethylene glycol with a molecular weight distribution of 3,300-3,800 .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
As polyethylene glycol with the molecular weight distribution of 3,300-3,800 is contained , the pharmaceutical composition for relaxing bowels and purging intestines provided by the invention not only has better effects of relaxing bowels and purging intestines than those of the existing medicines containing polyethylene glycol with a molecular weight of 4,000 and polyethylene glycol with a molecular weight of 3,350 , but also has the advantages of good taste and few side effects of bowels relaxing and intestines purging , so that the pharmaceutical composition is more helpful for the clinical treatment of the constipation and the preparation of cleaning the intestines before an operation .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also provides a preparation method of the pharmaceutical composition .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
By adopting the preparation method , the molecular weight distribution of polyethylene glycol which is the major ingredient of the pharmaceutical composition can be accurately controlled in a range of 3,300-3,800 .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A multi-element synergistic disinfecting analgetic with multiple functions and broad spectrum contains matrix , antibacterial antalgic compound , antimicrobial compound , quaternary ammonium salt compound , and/or chlorophenol compound .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Its application is also disclosed .
1 1 1 1 1 1 1 1 1 1
The invention discloses an N1 , N4-di-n-butyl-3 , 6-dimethyl-1 , 2 , 4 , 5-tetrazine-1 , 4-dicarboximide compound shown as a formula ( I ) as well as a preparation method and a purpose thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The compound is prepared by using 3 , 6-dimethyl-1 , 6-dihydro-1 , 2 , 4 , 5-tetrazine and triphosgene ( BTC ) as raw materials to take reaction with n-butylamine in organic solvents under the effect of base catalysis .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The compound is applied to the preparation of medicine for treating and preventing human gastric cancer and human ovarian cancer diseases .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The compound as well as the preparation method and the purpose have the advantages that the design is reasonable , the preparation method is simple and convenient , the operation is easy , the raw materials are easy to obtain , in addition , the production cost is low , the compound is suitable for industrial application , and a new variety is provided for the anti-tumor medicine screening .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention belongs to the technical field of medicine , and in particular relates to compounds which are shown in a general formula ( I ) and contain imidazopyridine , pharmaceutically acceptable salts of the same and isomers of the same , wherein R < 1 > , R < 2 > , R < 3 > , and X are defined in a specification .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also relates to a method for preparing the compounds , a pharmaceutical composition containing the compounds , and application of the compounds to preparation of medicines for preventing and/or treating peptic ulcer .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention discloses and claims a series of substituted N-phenyl-pyrrolidinylmethylpyrrolidine amides of formula ( I ) as described herein .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
More specifically , the compounds of this invention are modulators of H3 receptors and are , therefore , useful as pharmaceutical agents , especially in the treatment and/or prevention of a variety of diseases modulated by H3 receptors including diseases associated with the central nervous system .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Additionally , this invention also discloses methods of preparation of substituted pyrrolidinylmethylpyrrolidine amides and intermediates therefor .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention is useful as a HMG-Co A reductase inhibitor and relates to a new method for manufacturing pitavastatin hemicalcium which is used as a treatment for hyperlipidemia .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
More specifically , a new method for manufacturing pitavastatin hemicalcium using a new intermediate is disclosed .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention has the following advantages : the usage of the new intermediate for manufacturing pitavastatin provides a more effective method for manufacturing pitavastatin ; an alcohol protecting group , which is one of the new intermediates , easily protects dialcohol within one to two hours under acid catalyst and mild reaction conditions ; the deprotection reaction of dialcohol is completed within thirty minutes to one hour under very mild reaction conditions of 0 to 25 degrees celsius , which reduces the formation of isomers to the extent possible .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Also , the present invention is able to obtain a high yield of high purity pitavastatin hemicalcium despite consecutively executing a hydrolytic reaction and a pitavastatin hemicalcium reaction , without an isolation reaction after the deprotection reaction .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses children oral decayed-tooth spray containing marine biological ingredients and a preparation method thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The children oral decayed-tooth spray containing the marine biological ingredients disclosed by the invention comprises the following components in percentage by weight : 10-15 % of xylitol , 6-10 % of algal polysaccharides , 3-8 % of chitin , 5-8 % of marine biologic enzyme , 5-10 % of animal antimicrobial peptide , 0.05-1 % of edible essence , and the balance of purified water .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Because of containing the natural marine biological ingredients , the children oral decayed-tooth spray containing the marine biological ingredients disclosed by the invention is free from toxic and side effects , obvious in antibacterial and anti-inflammatory effects and convenient for use by being uniformly sprayed on the surface of teeth and is capable of eliminating malignant bacteria of oral inflammation , keeping oral flora balance and treating ulcer and inflammation rapidly and moderately .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
It is found that a nitrogenated heterocyclic derivative represented by the formula ( I ) can bind specifically to an NR1/NR2B receptor and can be used as an analgestic agent .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A compound represented by the formula ( I ) or a pharmaceutically acceptable salt thereof or the like : ( I ) wherein A1 represents a nitrogenated aromatic monocyclic group or nitrogenated aromatic fused-ring group which has at least one hydroxyl and/or amino and which may be substituted by other group or a nitrogenated aromatic monocyclic ring or nitrogenated aromatic fused-ring group which has -NH- in the ring and in which other ring-constituting atom may be substituted ; A2 represents an aromatic hydrocarbon cyclic group which may have a substituent or the like ; R1 and R2 independently represent a hydrogen , hydroxyl or the like ; m is 0 or 1 ; X represents a lower alkylene , -CO ( CR3R4 ) n- or -A3- ( CR3R4 ) n- which may have a substituent or the like ; Y represents a single bond , a lower alkylene or the like ; and R3 to R15 independently represent a hydrogen , a lower alkyl or the like .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention provides a method for forecasting , preventing and treating septicemia and septic shock and a kit , particularly a protein CRISPLD2 related to septicemia and septic shock .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention can be used for preventing and treating septicemia and septic shock by improving the concentration of the CRISPLD2 protein in serum .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also discloses a corresponding CRISPLD2 protein and an application thereof as a promoting agent .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention relates to a drug for curing car sickness , sea sickness and air sickness .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
It is characterized by that it includes ( wt % ) 10 % of dimenhydrinate and 1 % of anisodamine ( 654-2 ) .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a febuxostat dispersible tablet drug and a preparing method .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The drug is prepared from febuxostat as the active drug ingredient , and acceptable auxiliary ingredients in the dispersible tablet preparation .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The febuxostat dispersible tablet drug is characterized in that at least one of polyoxyethylene 40 monostearate ingredient , polyethenoxy ether castor oil ingredient and hydrogenated castor oil polyoxyl ingredient in the auxiliary ingredients is used as a solubilizing agent ingredient and has the usage amount of 0.1-5 times the weight of febuxostat .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The drug can obviously enhance the dissolution rate of the insoluble effective drug ingredient of febuxostat , and has the advantages of high drug dispersion degree , high dissolution rate , quick absorption and effect taking , high biological utilization degree , and the like .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention relates to a compound of formula I ( I ) wherein X is hydrogen , R1 , RIC ( O ) , R1C02 , or a C0X2 inhibitor , wherein R1 is C1-20 alkyl , aryl , arylalkyl , alkyloxy or arylalkyloxy ; wherein Y is 0R2 , NHR3 N ( R3 ) 2 , or a COX inhibitor ; wherein R2 is hydrogen or C1-20 alkyl and each R3 is independently hydrogen or a C1-4 alkyl ; wherein T is 0R4 , NHR5 N ( R5 ) 2 , or a COX inhibitor ; wherein R4 is hydrogen or C1-20 alkyl and each R5 is independently hydrogen or a C1-4 alkyl ; wherein Z is hydrogen , R6 , R6C ( 0 ) , R6CO2 , or a C0X2 inhibitor ; wherein R6 is C1-20 alkyl , aryl , arylalkyl , alkyloxy or arylalkyloxy ; with the proviso wherein when X and Z are hydrogen and T is OH , Y is not OH ; for use in the prevention and/or treatment of pain wherein said compound is provided for systemic administration .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Self-reinforced tissue shields are useful as ophthalmic shields , wound dressings , wound barriers , nerve repair , therapeutic drug delivery devices and the like .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The self-reinforced tissue protective shields comprise gelatin , chitosan and reinforce and are made by a method comprising forming inter-molecular locking within a solution through electrostatic forces , eliminating the use of extra cross-linking methods , the solution mainly comprising natural existing polymers that are biodegradable and biocompatible .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses an antitumor isoliquiritigenin tablet .
1 1 1 1 1 1 1 1 1 1 1 1
The isoliquiritigenin is used as an effective component to prepare antitumor tablet .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The antitumor isoliquiritigenin tablet contains isoliquiritigenin , filler , adhesive , disintegrant , wetting agen and lubricant , which are proportioned according to a certain proportion .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The formula is reasonable and the use is convenient .
1 1 1 1 1 1 1 1 1 1 1 1 1 1
The drug combination prepared in the method has good antitumor function , good treating effects and low side effects .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Compounds are provided having the formula : wherein variables Ra , R1 , R2 , R3 , R4 , A1 , A4 , L , Q , X and subscript n as described herein .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The subject compounds are useful for treatment of inflammatory and immune conditions and diseases .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Compositions and methods of treatment using the subject compounds are also provided .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
For example , the subject methods are useful for treatment of inflammatory and immune disorders and disease such as multiple sclerosis , rheumatoid arthritis , psoriasis , and inflammatory bowel disease .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses a process for producing dry bacterial powder which contains gamma-linolenic acid , comprising the following steps of screening strain , inclined surface vibrating culture , multi-stage fermentation , filtering , dehydration , drying , crushing and packaging .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Further , the improvement of the invention is that the dying procedure is realized under the condition of -40 to 30 DEG C. The specific process includes that the vibrating drying is proceeded on the condition of 20-30 DEG C and 0.4-0.6 Pascal , or the drying is proceeded by utilizing air of which the moisture degree is 20 % to 30 % in the manner of vibration under the condition of -40 to 20 DEG C. The invention ensures the survival rate of bacterium through improving the drying art , thereby guaranteeing the quality of gamma-linolenic acid , and improving the quality of the final product .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also provides the specific art parameter of each procedure and is capable of further ensuring the achievement of fine-quality products .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Compositions suitable for enhancing the antioxidant status of animals containing methionine , taurine , vitamin C , and vitamin E and methods for preparing and using such compositions to enhance the antioxidant status of animals are disclosed .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a baby nasal spray and a preparation method thereof , belonging to the technical field of medical health care .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The preparation method comprises the following steps of : respectively preparing xylitol/xylose and sodium chloride into 5-90 % solution and 0.5-10 % solution according to the weight percentage , mixing the two solution according to the amount of dry mass ratio of 5-65:1 , adding 0.01-0.1 % benzalkonium chloride or 0.001-0.1 % benzyl alcohol according to the weight percentage as a preservative , and uniformly stirring at 20-80 DEG C to obtain the nasal spray .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The nasal spray prepared by adopting the xylitol saline solution can effectively treat nasopharyngitis , reduce the infectious dose of nasopharyngitis bacteria , can not generate resistance , can reduce the dependence on antibiotic , effectively prevents otitis and sinusitis and remarkably improves asthma caused by infection of the upper respiratory tract .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention relates to a novelsynergistic pharmaceutical composition for serotonin reuptake inhibition , wherein thesaid composition comprises pentacyclic terpenoid glycosides , preferably asiaticoside and madecassoside optionally along with excipients .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Also the present invention relates toexcipients ; a process of preparation of novelsynergistic pharmaceutical composition for serotonin reuptake inhibition , wherein the process comprising steps of : ( a ) obtaining extract from the plant Centella asiatica ; ( b ) treating the extract with the solvents to remove fatty substances , chlorophyll and other colorants ; ( c ) purifying the extract through HPLC to obtain the eluted solvent ; and ( d ) concentrating the eluted solvent to arrive at the composition .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also relates to thecomposition ; and use of a composition comprising pentacyclic terpenoid glycosides , preferably asiaticoside and madecassoside optionally along with excipients to manufacture a medicament for serotonin reuptake inhibition in a subject in need thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention relates to novel hydrazide group containing carbamate prodrugs of phenolic drugs of formula ( I ) or pharmaceutically acceptable salt thereof , and process for the preparation thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Compound of formula ( I ) : wherein : R1 and R2 , which may be identical or different , each represents hydrogen , acyl or alkyl , Ar represents aryl or heteroaryl , A represents a group selected from : R4 represents hydrogen or alkyl , R5 represents hydrogen , alkyl , aryl or heteroaryl , R3 represents aryl , heteroaryl , dicyclopropylmethyl or benzhydryl , or A-R3 represents an optionally substituted naphthyl group , with the exclusion of 2,5-dihydroxy-3- ( 4-methoxyphenyl ) -6- ( 2-phenylethenyl ) -1,4-benzoquinone , 2,5-dihydroxy-3- ( 4-methoxyphenyl ) -6- ( 2-naphthyl ) -1,4-benzoquinone and 2,5-dihydroxy-3- ( 2-naphthyl ) -6-phenyl-1,4-benzoquinone .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Medicinal products containing the same which are useful in the treatment of diseases associated with a deregulation of glycaemia .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Solid calcium lactate in the form of substantially spherical particles , characterised in that the spherical particles have a particle size distribution such that most of the particles are between 280 and 550 microns in size and the calcium lactate can be rapidly dissolved in water .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A pharmaceutical aerosol formulation suitable for oral and/or nasal inhalation including the anti-inflammatory drug ciclesonide , hydrofluorocarbon propellants such as HFC 134a and/or 227 , and ethanol in an amount sufficient to solubilize the ciclesonide ( and various optional ingredients , such as surfactant ) .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The formulations exhibit very desirable physical and chemical stability , as well as excellent delivery characteristics .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses a pharmaceutical composition for treating pancreatic cancer , and the pharmaceutical composition comprises gemcitabine and tetrahydropyrimidine or tetrahydropyrimidine derivatives used as active ingredients , wherein the tetrahydropyrimidine derivatives include 1,4,5,6-tetrahydro-2-methyl-5-hydroxy-4-pyrimidinecarboxylic acid and the like .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The mass ratio of gemcitabine to tetrahydropyrimidine or tetrahydropyrimidine derivatives in the composition is 3:1 .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The inventor found in pharmacodynamic studies that the combination of gemcitabine and tetrahydropyrimidine or tetrahydropyrimidine derivatives in a certain proportion has distinct therapeutic effect on pancreatic cancer .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Tetrahydropyrimidine or tetrahydropyrimidine derivatives can improve the therapeutic effect of gemcitabine on pancreatic cancer , and can reduce the toxicity of gemcitabine .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging , diagnosis and treatment of conditions involving the vascular endothelium .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a preparation method of silkworm chrysalis chitosan derivatives CS-B-R with anticoagulation activities , wherein the CS is a chitosan molecule which is extracted from the silkworm chrysalis and contains active groups such as -NH2 , -OH and the like ; B is a linking group such as a propyl group , an ethyl group and the like ; R is a molecule chain section which contains -NH , -COOH and the like and can be subjected to complexing with calcium ions .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The preparation method is as follows : preparing an intermediate with a halogenation activity by using corresponding amino acid and epoxy chloropropane or ethylene hydrocarbon ; and reacting the intermediate with the chitosan extracted from the silkworm chrysalis so as to obtain the product .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The derivatives are simple in preparation process , can be directly dissolved in water and have the advantages of good anticoagulation effect , good biocompatibility and wide medicine application prospect .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses a medicine for the treatment of a gastric disease , which is prepared from furazolidone , liquorice and cortex ilicis rotundae on the basis of the combination of Chinese and Western medicines , has no toxic and side effects and is moderate in nature , sweet in taste and not cold and hot .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
After the medicine is taken , gastric juice and gastric mucosa can be dissipated to lead the medicine to direct contact with focus of disease , thereby achieving the treating effect .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a faint yellow powder which is provided with an effective part with hypoglycemic activity , and is prepared by smashing the ramulus mori , extracting the ramulus mori by water and/or alcohol , or extracting the ramulus mori by acid water , decontaminating in an alcohol deposition or flocculation way , concentrating , and separating and refining by a resin chromatography method .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The effective part of the faint yellow powder provided by the invention , namely a hypoglycemic active ingredient , is a group of polyhydroxy alkaloids .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The test by a HPLC ( high performance liquid chromatography ) method shows that the weight percentage of the total alkaloid in the effective part is more than 50 % .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The hypoglycemic dosage is 12.5-200mg for each person at every turn ( by total alkaloid ) .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention is directed to compounds of formula I-V and tattooers thereof or pharmaceutically acceptable salts , esters , and pro drugs thereof which are inhibitors of sky kinase .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention is also directed to intermediates used in making such compounds , the preparation of such a compound , pharmaceutical compositions containing such a compound , methods of inhibition syk kinase activity , methods of inhibition the platelet aggregation , and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity , such as undesired thrombosis and Non Hodgkin 's Lymphoma .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Exemplary compositions include RGD-polyphenol conjugates via an ester linkage ; polyphenol polymer conjugated to RGD analogs or mimetics ; and RGD polymer conjugates linked to polyphenol .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention provides a compound which elevates intracellular calcium for use in the treatment of a disease which has a Niemann-Pick disease type C like cellular phenotype .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention further provides a compound which reduces sphingosine storage for use in the treatment of Niemann-Pick disease type C .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention is one novel medicine package for preventing and treating women 's cervical virus infection , and the medicine package has novel medicine recipe , novel medicine form and novel medicine transfer device .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The medicine package is for treating chronic cervicitis caused by sexually transmitted cervical human papilloma virus ( HPV ) , herpes simplex virus II ( HSV-2 ) , cytomegalovirus ( CMV ) , etc and cervical epithelium maldevelopment .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
It has the functions of inhibiting virus propagation and preventing cervical carcinoma .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention has unique medicine recipe , special medicine transfer mode , accurate administration to the pathological cervical part , high local medicine concentration , lasting medicine action period and raised antiviral effect .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The cervical Papanicolaou smear examination reveals that the present invention is advance and effective .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Novel crystalline forms of a compound of formula ( 1 ) are disclosed .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Also disclosed are pharmaceutical compositions comprising theses forms , and methods of their preparation and use .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses new application of 6-gingerol .
1 1 1 1 1 1 1 1 1 1 1 1
The 6-gingerol is used for respectively regulating M8 and V1 subtype transient receptor potential ion channels ( short for TRPM8 and TRPV1 ) of mammals including humans and can be also used for preparing medicaments for treating related diseases , such as cryalgesia allergy , the parkinsonism , painful bladder syndrome , chronic obstructive pulmonary diseases , and the like as well as tumors of skin , the prostate gland , the mammary gland , the lung , the colon , and the like , participated by the ion channels .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The action intensity of the 6-gingerol is higher than that of capsaicin .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed is a preparation containing at least one form of lipid nanoparticles or a nanoemulsion , containing at least one compound of formula I and/or a stereoisomeric form of the compound of formula I , in which R1 represents - ( C5-C17 ) alkyl or - ( C5-C17 ) alkenyl .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Said preparation is suitable for treating androgenetic alopecia , hirsutism , i.e .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
the prevention of undesired hair growth , seborrhoea , and acne and can also be used in cosmetics .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Compounds represented by the general formula [ | ] or pharmacologically acceptable salts thereof : [ | ] wherein G1 is halogeno , alkyl which may be substituted with alkoxy , or a group represented by the general formula [ || ] : [ || ] ( wherein B is optionally substituted benzene or the like ; and W is a single bond or C1-4 alkylene which may be substituted with one or two alkyl groups ) ; Q1 and Q2 may be the same or different and are each hydrogen , halogeno , or alkyl ; n is 0 , 1 , 2 , 3 , or 4 ; R1 is hydrogen , optionally substituted alkyl , optionally substituted cycloalkyl , optionally substituted phenyl , or the like ; Z1 , Z2 , Z3 , and Z4 may be the same or different and are each CH or N , with the proviso that three or more of Z1 , Z2 , Z3 , and Z4 are not simultaneously N ; G2 is hydrogen , -NR3R4 , -OR5 , or the like ; and R3 to R8 are each independently hydrogen , optionally substituted alkyl , alkenyl , alkynyl , or the like .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to application of an aromatase inhibitor in preparation of anti-cirrhosis or anti-liver fibrosis drugs .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The aromatase inhibitor particularly can be exemestane , formestane , letrozole or anastrozole , and they can all reach good effects in anti-fibrosis and anti-cirrhosis aspects .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A new immunosuppressive agent as glycyrol has significant immunosuppressive activity , thus is useful as an immunosuppressive agent to treat relative diseases , wherein the glycyrol is a coumestrol compound extracted from glycyrrhiza , which is a small molecular compound with novel chemical structure .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Tests prove that the glycyrol can inhibit the increment of T lymphocyte induced by canavaline A and inhibit one-way mixed lymphocyte reaction ( MLR ) , release the inflammatory symptom of delayed hypersensitivity and inhibit the homologous allogenic organ transplantation rejection .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The glycyrol is a high-effective low-toxicity immunosuppressive agent , with small molecular weight and simple structure , which is easy to be modified and to prepare different drug agents , therefore , the compound is a new generation immunosuppressive agent .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed herein are methods of treating therapeutically , or metaphylactically infected animals susceptible to , or infected animal suffering from parasitic neurologic or abortigenic diseases due to Sarcocystis , Neospora or Toxoplasma that are treatable with triazineone compounds by administering thereto a pharmaceutically effective amount of the compound , including a single high dose therapeutic treatment .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to modified hepatitis C virus E2 polypeptides that are effective in eliciting the production of cross-neutralizing antibodies against hepatitis C virus .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention provides modified hepatitis C virus E2 polypeptides , preparations and pharmaceutical compositions containing them , as well as methods for using these modified E2 polypeptides .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A novel nucleic acid construct for down-regulating angiogenesis in a tissue of a subject is provided .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The nucleic acid construct includes : ( a ) a first polynucleotide region encoding a chimeric polypeptide including a ligand binding domain fused to an effector domain of an apoptosis signaling molecule ; and ( b ) a second polynucleotide region encoding a cis acting regulatory element being for directing expression of the chimeric polypeptide in a specific tissue or cell ; wherein the ligand binding domain is selected such that it is capable of binding a ligand present in the specific tissue or cell , whereas binding of the ligand to the ligand binding domain activates the effector domain of the apoptosis signaling molecule .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Also provided are methods of utilizing this nucleic acid construct for treating diseases characterized by excessive or aberrant neo-vascularization or cell growth .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a stilbene glucoside medical composite and a preparation method thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The stability of the medical composite in the solid state or the liquid state is greatly improved ; and the preparation method is convenient and feasible and is suitable for industrial production .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testosterone over periods of time .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Further provided are methods of treating andro- and/or testosterone deficiency in individuals by administering to the individuals compositions described herein .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to an injection containing ibuprofen and a preparation method of the injection .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A metal ion chelator in the injection is ethylene diamine tetraacetic acid disodium or ethylene diamine tetraacetic acid calcium sodium ; small white spots and an ibuprofen injection of which the number of visible foreign matters is remarkably reduced can be obtained by controlling the weight percentage of the metal ion chelator to be 0.05-0.48 percent ; and when an internal coating material of the injection is neutral borosilicate glass ampoule , an ibuprofen injection with stable quality and favorable clarity can be obtained ; and the problem that the visible foreign matters are easily generated in the large-scale industrial production of the domestic ibuprofen injection at present is solved .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
In addition , the injection is simple in production process , controllable in quality and is more suitable for industrial production .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Medical combination and its method of topical use comprising active ingredients which are sparingly soluble in water , preferably in one single composition against microbes which are pathogenic in humans and animals and which usually appear together .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
It comprises at least one active ingredient which is effective against several of the opportunally pathogenic strains of the group consisting of fungi Candida , Aspergillus , and/or Fusarium , and aerobic bacteria : Gram-negative bacilli such as Proteus , Pseudomonas , enterobacter species , Escherichia coli , Klebsiella , Serratia marcescens , Citrobacter , Aeromonas ; Gram-negative cocci such as Neisseria , Acinetobacter species ; Gram-positive bacilli such as Corynebacterium speies , Bacillus sphaericus , Gram-positive cocci such as Streptococcus species ; anaerobic bacteria : Gram-negative cocci such as Bacteroides , Fusobacteria ; Gram-positive cocci such as Peptococcus , Peptostreptococcus species ; Gram-positive bacilli such as Clostridium , Propionibacterium , Eubacterium species and Mycobacterium species suh as Mycobacterium ulcerans , microbes similar to bacteria of the Chlamydia species such as Chlamydia trachomatis .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
To be used for treatment of the skin or mucous membranes bearing epithelial lesions , deficiency or injuries and to be used in body cavities to prevent or cure infections and deficiencies .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The composition contains-dispersed in a carrier which is pharmaceutically acceptable on the site of treatment-at least one fungicide , which is preferably azole or polyene type and at least one antibacterial compound preferably of the erythromycin , azalide , linkozamide , polypeptide type and at least one bacteriostatic sulphonamide .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Additionals mainly for use on skin may include zinc oxide and asulene .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Useful in forms of ointment , tablet , effervescent tablet , suppository , foam .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
This invention provides a method of modulating translation termination efficiency of mRNA and/or promoting degradation of aberrant transcripts .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Also , this invention provides a method of screening for a drug active involved in enhancing translation termination and a method for identifying a disease state involving defective the protein complex .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
This invention provides a purified complex comprising an amount of a human Upflp protein , a peptidyl eucaryotic release factor 1 ( eRF1 ) and a peptidyl eucaryotic release factor 3 ( eRF3 ) effective to modulate translation termination .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Further , this invention provides an expression vector which comprises a nucleic acid encoding a human Upflp protein , a peptidyl eucaryotic release factor 1 ( eRF1 ) and a peptidyl eucaryotic release factor 3 ( eRF3 ) operably linked to a regulatory element .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
This invention provides an antibody which binds to the complex comprising an amount of a human Upflp protein , a peptidyl eucaryotic release factor 1 ( eRF1 ) and a peptidyl eucaryotic release factor 3 ( eRF3 ) effective to modulate translation termination .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
This invention provides an agent which inhibits or modulates the binding of human Upflp to eRF1 or eRF3 .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The agent may inhibit or facilitate the binding of human Upflp to eRF1 or eRF3 .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses a preparation method of a copper and zinc coordination compound of urocanic acid/attapulgite based antibacterial agent and applications thereof , wherein the preparation method comprises the following steps : A1 .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
the preparation of amino attapulgit ; A2 .
1 1 1 1 1 1 1 1 1 1 1 1
the preparation of urocanic acid/attapulgite ; and A3 .
1 1 1 1 1 1 1 1 1 1 1 1 1
the preparation of the urocanic acid Cu2 < + > , Zn2 < + > coordination compound/attapulgite antibacterial agent .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The urocanic acid coordination compound/attapulgite antibacterial agent has favorable antibacterial effect on escherichia coli , and the antibacterial effect is relatively stable ; the mass concentration is 3g/L , the antibacterial ratio of escherichia coli for 24 hours by zinc coordination compound of urocanic acid/attapulgite can reach 98 % , and the antibacterial ratio of escherichia coli for 24 hours by the copper coordination compound/attapulgite can reach 87 % ; and integrating the influences to human bodies by zinc and copper ions as well as the antibacterial capability of the antibacterial agent , the zinc coordinate compound of urocanic acid/attapulgite is an external applied antibacterial agent with greater develop prospect .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed are : a compound represented by formula ( I ) [ wherein m represents a number of 0 to 2 ; n represents a number of 1 or 2 ; p represents a number of 0 to 2 ; q represents a number of 0 or 1 ; R1 represents a halogen , a C1-2 alkyl , or the like ; R2 represents a halogen , a C1-5 ( substituted ) alkyl , or the like ; R3 represents a hydrogen atom , a halogen , a ( halogen-substituted ) C1-6 alkyl , or the like ; X1 represents O or -NR6- ; X2 represents a methylene , O or -NH- ; Y represents a single bond , or a ( halogen-substituted ) C1-4 alkylene group ; G1 and G2 independently represent N or C-R7 ; and the moiety represented by `` Cycle '' represents a 5- to 6-membered aryl which may have one or two members selected from N , O and S ] , a salt of the compound , or a solvate of the compound or the salt ; and a pharmaceutical composition and a TRPV1 receptor modulator each comprising the compound , the salt or the solvate as an active ingredient .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention provides an application of ursolic acid saponin and oleanolic acid saponin with a general formula I in the preparation of medicines for increasing leucocyte and/or blood platelet .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also provides a medicine combination with the chemical compound .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention adopts the low-cost ursolic acid and oleanolic acid which is easily available from natural products and introduces monosaccharide and oligosaccharyl through structure modification .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Pharmacology experiments prove that the invention can notably increase the leucocyte and/or the blood platelet .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses an extraction method of honeysuckle chlorogenic acid .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The method provided in the invention has the advantages that : the honeysuckle raw material is processed by a superfine grinding process , the particle size distribution is uniform , the original physicochemical properties are kept , the bioavailability is high , a freshness retaining effect of honeysuckle can be achieved , and simultaneously the grinding process has certain sterilization function ; by high speed centrifugation , loss of effective components can be effectively prevented , so that high purity honeysuckle chlorogenic acid crystals can be obtained ; the high purity honeysuckle chlorogenic acid crystals obtained by a microencapsulation treatment is beneficial to long-term storage ; the adding of microencapsulated catechin-tea flavonoid crystals is conducive to better playing an antibacterial and antiviral role the role ; and silver ions are more in favor of bringing the sterilizing and virus-killing functions of catechin-tea flavonoid into play .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention provides an amorphous , lyophilized , parenteral formulation of olanzapine .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a composition for suppressing target gene expression , which contains siRNA as an active component that can specifically suppress the target gene expression .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The composition also comprises fluoroquinolone , wherein the mol ratio of the siRNA and the fluoroquinolone is from 1:5*10 < 2 > to 1:1*10 < 7 > .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The composition for suppressing target gene expression comprises the siRNA andthe fluoroquinolone , the fluoroquinolone can increase the efficiency of the siRNA , disclosed as a picture 3 , the effective concentration of 50 percent ( EC50 ) of enoxacin is about 30 micrometers , and therefore , the composition can more effectively suppress the target gene expression .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Compared with the singly used siRNA , the composition can realize the needed suppression effect under lower siRNA concentration , thereby reducing to miss targets ; moreover , in an effective concentration range , the fluoroquinolone can not influence the normal functions of cells and organisms , and therefore , the composition is safe .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed herein are deuterium-enriched colchicine , thiocolchicine , and derivatives thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The deuterium-enriched compounds are useful as , an antiproliferative agent , a muscle relaxant , an anti-inflammatory agent , or an anti-gout agent .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention is a composition delivering effective amounts of Glucosamine , Devils Claw , and SAM in a single dosage unit .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention relates to the identification and use of compounds that are inhibitors of the alanine-serine-cysteine transporter 1 ( asc-1 ) .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
This includes an assay for the identification of compounds that are inhibitors of asc-1 , as well as pharmaceutical compositions comprising these compounds .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also comprises a method for the use of these compositions for the treatment , alleviation or amelioration of memory and attention deficits resulting from but not limited to Alzheimer 's disease , Parkinson 's disease , trauma and stroke , and for enhancement of learning and memory ability in a human not suffering from any neurological disorders .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Finally , the invention comprises methods for use of the compositions for alleviation or amelioration of conditions in which there is altered glutamatergic or dopaminergic neurotransmission such as schizophrenia , Parkinson 's disease , epilepsy , depression , obsessive compulsive disorders and bipolar disorders .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Chondroitin , a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms , possesses biological properties different from those of chondroitin sulphate , and can be advantageously used for applications in the pharmaceutical , nutraceutical , cosmeceutical and medical device fields .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Chondroitin has biostimulating , anti-inflammatory and antimicrobial activity and can be used in the treatment of osteoarthritis , eye disorders , interstitial cystitis , lung disorders , inflammatory disorders in general , oncological disorders , peritoneal dialysis , tissue biorevitalisation and wound repair , as a skin filler , and as bioresorbable scaffolds .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention relates to a composition and health functional food for inhibiting apoptosis of cranial nerve cells , and to a method for inhibiting apoptosis , wherein the composition and health functional food comprising a phosphodiesterase type 5 active inhibitor .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
According to the present invention , the PDE5 inhibitor exhibits a protective effect on nerve cells by inhibiting apoptosis of cranial nerve cells .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Thus , the present invention can be effectively used to prevent , alleviate , and treat cranial nerve disease .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A compound of formula 1 , wherein X , Z , R1 to R10 , R15 , R16 , m , n , r and t are as defined in claim 1 , or a pharmaceutically acceptable salt or ester thereof , useful as an alpha-2 antagonist .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The compounds of formula I can be used for the treatment of diseases or conditions where antagonists of alpha-2 adrenoceptors are indicated to be effective .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Effective treatments of periodontal disease for extended periods of time are provided .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Through the administration of an effective amount of clonidine , sulindac , and/or fluocinolone at or near a target site , one can reduce , prevent , and/or treat periodontal disease .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
In some embodiments , when appropriate formulations are provided within biodegradable polymers , treatment can be continued for at least two weeks to two months .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a medicament for preventing and/or treating schizophrenia which comprises as an active ingredient cilostazol or a pharmaceutically acceptable salt thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention provides an N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative of formula ( I ) or a pharmaceutically acceptable salt thereof , a method for preparing same , and a pharmaceutical composition comprising same as an active ingredient .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The inventive N1-2-thiophen-2-ylethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs , and thus , it is useful for preventing or treating diabetes , metabolic syndromes such as insulin-independent diabetes , obesity and atherosclerosis , or a P53 gene defect-related cancer .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Provided are : a lipase activity inhibitor having excellent lipase activity inhibitory action ; a cosmetic containing said lipase activity inhibitor ; use of a phospholipid for manufacturing said cosmetic ; use of a phospholipid for manufacturing a drug , anti-acne agent , anti-obesity agent or anti-inflammatory agent containing said lipase activity inhibitor ; a phospholipid for use in inhibiting lipase activity ; a phospholipid for use in preventing or treating acne , obesity or inflammation ; and a method for preventing or treating acne , obesity or inflammation , including administration of said phospholipids .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention pertains to : a lipase activity inhibitor containing a phospholipid as the active ingredient , and a cosmetic , drug , anti-acne agent , anti-obesity agent or anti-inflammatory agent containing said lipase activity inhibitor ; use of a phospholipid for manufacturing said cosmetic , drug , anti-acne agent , anti-obesity agent or anti-inflammatory agent ; a phospholipid for use in inhibiting lipase activity ; a phospholipid for use in preventing or treating acne , obesity or inflammation ; and a method for preventing or treating acne , obesity or inflammation , including administration of said phospholipids .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A first embodiment can be a method to reduce SLOSH energy absorption within an organism by reducing the inelastic collisions .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A fluid containing organism can utilize an embodiment of the method wherein one or more of reversibly increasing pressure within the organs or cells , reversibly increasing the volume within the organs or cells , reversibly altering vascular , molecular , or cell wall stiffness , or reversibly altering vascular , molecular , or cell wall configuration within said organism may reduce these collisions .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed are compounds represented by formulae I , II , and III , and the compositions and methods thereof for treating viral infections caused by a Flaviviridae family virus .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to configurational isomers 4-hydroxyisoleucine , and to lactones , pharmaceutically acceptable salts , and prodrugs thereof , to processes for their preparation , and to pharmaceutical compositions comprising the same .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The isomers of the invention exhibit insulinotropic activity and thus may be useful for the prevention and treatment of disorders of carbohydrate or lipid metabolism , including diabetes mellitus ( type 1 and type 2 diabetes ) , pre-diabetes , and Metabolic Syndrome .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to 5-fluorouracil-sn2-phosphatidylcholine copolymers and a preparation method and application thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The preparation method comprises : preparing 5-fluorouracil derivatives containing carboxyl groups , using a carboxylic group as a connecting group to covalently bond 5-fluorouracil on a sn2 site of phosphatidylcholine , and obtaining the copolymers .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The copolymers have amphiphilic surface activity , can form liposome nano-capsules and a self-assembly delivery system , and can be taken as an intermediate preparation formulation and further prepared into a corresponding transdermal delivery preparation such as gel .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The copolymers and the delivery system of the copolymers can effectively enter focuses , and can be subjected to enzymolysis through high-expression phospholipase A2 on the focuses to metabolize active skin cancer resistant medicines , namely the 5-fluorouracil , so that the copolymers and the delivery system have the advantage of skin-targeted medication of skin cancer , overcomes the defects that the water-soluble 5-fluorouracil is not suitable for transdermal administration and has low envelop rate of liposome , easy leakage and difficult acquisition of liposome with superior transdermal carrier performance , and provides a novel medicine source for clinical medicines .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a vaginal expansion suppository containing econazole or an econazole salt .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The expansion suppository comprises econazole or the econazole salt , a liposolubility matrix and an expansion carrier .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
When the suppository is fully expanded , a medicinal layer can be in full contact with an inner wall of a vagina , so as to prevent a medicinal liquid from outflowing .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The expansion suppository also comprises a tert-butyl hydroxy compound which can prevent econazole from being oxidized so as to improve the stability of econazole .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also provides a preparation method and detection methods of the expansion suppository .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The vaginal expansion suppository containing econazole or the econazole salt employs seven original leading technologies , and also has the beneficial effects that : the expansion suppository prevents the medicinal liquid from outflowing , has high stability and lasting effect of treatment , and prevents secondary infection .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
This invention relates to compositions comprising thalidomide and another anti-cancer drug which can be used in the treatment or prevention of cancer .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Preferred anti-cancer drugs are topoisomerase inhibitors .
1 1 1 1 1 1 1 1 1 1 1
A particular composition comprises thalidomide , or a pharmaceutically acceptable salt , solvate , or clathrate thereof , and irinotecan .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also relates to methods of treating or preventing cancer which comprise the administration of a thalidomide and another anti-cancer drug to a patient in need of such treatment or prevention .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention further relates to methods of reducing or avoiding adverse side effects associated with the administration of chemotherapy or radiation therapy which comprise the administration of thalidomide to a patient in need of such reduction or avoidance .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A compound of the invention , when administered by any of a number of administration routes , exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention is directed to methods of bone healing by administering a p38 MAP kinase inhibitor .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention is directed to methods of treating bone fractures , bone diseases , bone grafting , especially enhancing bone healing following facial reconstruction , maxillary reconstruction , mandibular reconstruction or tooth extraction , enhancing long bone extension , enhancing prosthetic ingrowth , and increasing bone synostosis by administering a p38 MAP kinase inhibitor .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A derivative of the borneol ester of fatty acid , which is a target auxiliary of the medicine for treating cerebral diseases , is prepared through esterifying reaction between borneol or isoborneol and the straight-chain or branch-chani C5-C30 fatty acid .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to bipyridine alkaloid compounds and a preparation method and use thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The compounds with novel structures are produced by Actinoalloteichus sp.WH1-2216-6 separated from a marine sample .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Experiments prove that the compounds can serve as cell proliferation inhibitor or antineoplastic agent .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
It relates to a device comprising ( a ) a core comprising polyurethane ; ( b ) a sheath comprising ethylene vinyl acetate copolymer , said sheath substantially or completely surrounding said core ; and ( c ) one or more active pharmaceutical ingredients dissolved or dispersed in said core and/or said sheath ; and to a process for its preparation .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present application includes novel modulators of TLRs , compositions containing such compounds , therapeutic methods that include the administration of such compounds .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
This invention concerns a the maleic acid trimebutine sustained-releasing tablets with rapid releasing part and preparation of pharmaceutical pharmaceuticals , including double slice and tablet mixed and suppressed by particles with different releasing characteristics , it is found in the invention that after the maleic acid trimebutine and fumaric acid being mixed and granulated , the stability and compressibility of the maleic acid trimebutine is improved , and its citation moist is lowered , and it can be used for preparation of the praeparatum of the present invention , the present invention includes the rapid releasing part and sustained-releasing part .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A method of inhibiting COX-2 , inhibiting NF-Kappa B activation , treating inflammation , or treating cancer may comprise administering a therapeutically effective amount of an extract of Salacia cuspidata to a patient .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A medicament as described herein may comprise a pharmaceutically acceptable vehicle and a therapeutically effective amount of an extract of Salacia cuspidata suspended in the vehicle .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A method of making an extract of Salacia cuspidata may comprise creating a component solution by treating Salacia cuspidata material with an extractor and a solvent and producing an extract by at least partially removing liquid from the component solution .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
An extract of Salacia cuspidata may comprise components extracted using various solvents .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
An antibacterial agent for drug-resistant bacteria , which comprises either nibomycin and/or a derivative thereof and is effective on drug-resistant bacteria each having resistance to at least one drug .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a walnut ointment preparation method , which comprises the flowing steps of : steaming big walnut kernels , sesame oil and white sugar ; grinding the materials into paste ; sufficiently stirring the paste ; and filling the materials into a container to be sealed .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The walnut ointment has good effect on various kinds of calculus , is simple and convenient to use , can be easily implemented and has no toxic or side effect .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed is an anti-cancer agent characterized by comprising at least one phosphine transition metal complex selected from compounds respectively represented by formulae ( 1a ) to ( 1c ) .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The anti-cancer agent has an equivalent anti-cancer activity to those of conventional anti-cancer agents and has low toxicity .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
[ In the formulae , R1 and R2 independently represent a linear or branched alkyl group , a cycloalkyl group , a cyclcoalkyl group having a substituent , an adamantyl group , a phenyl group , or a phenyl group having a substituent , wherein each of R1 and R2 has 1 to 10 carbon atoms , R1 and R2 are different from each other , and R1 has a higher priority than R2 as ranked in accordance with the RS system ; R3 and R4 independently represent a hydrogen atom , or a linear or branched alkyl group , wherein each of R3 and R4 has 1 to 6 carbon atoms , R3 and R4 may be the same as or different from each other , R3 and R4 may together form a saturated or unsaturated ring that may have a substituent ; M represents a transition metal atom selected from the group consisting of gold , copper and silver ; and X- represents an anion .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed is a compound preparation wherein the bone cell activator is a vitamin D metabolite or vitamin D analogue and the resorption inhibitor is an oestrogenic compound .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The inventive compound preparation is used in a therapeutical plan which comprises one or more cycles .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Each cycle consists of the following steps : a ) daily administration of a vitamin D metabolite or vitamin D analogue during 1-7 days , b ) daily administration of an oestrogenic compound during 21-120 days after a ) or after an interphase of up to 30 days .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Compounds of Formula I : ( Formula should be inserted here ) and stereoisomers and pharmaceutically acceptable salts and solvates thereof in which R1 , R2 , R3 , R4 , R5 , R6 , R7 , X1 and X2 have the meanings given in the specification , are inhibitors of one or more JAK kinases and are useful in the treatment of autoimmune diseases , inflammatory diseases , rejection of transplanted organs , tissues and cells , as well as hematologic disorders and malignancies and their co-morbidities .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention provides a method of inhibiting tumor growth in a mammal , by administering to the mammal composition containing taurolidine , taurultam , or a biologically active derivative thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention provides a medicine composition and a health food for resisting liver fibrosis or cirrhosis , comprising an active component , for example ( xanthone derivative ) , and an admissible carrier .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention provides a method for stimulating an immune response by administering to a lymphoid cells either in a lymphoid organ or ex vivo , a nucleic acid molecule comprising a hematopoietic cell-specific expression element operationally linked to a nucleic acid sequence encoding one or more heterologous epitopes .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The heterologous epitope can be inserted into a complementarity-determining region of an immunoglobulin molecule .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention also provides a nucleic acid molecule comprising a hematopoietic cell-specific expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention additionally provides a method of treating a condition by administering a nucleic acid molecule comprising a hematopoietic cell-specific expression element operationally linked to a nucleic acid sequence encoding a heterologous polypeptide , wherein the nucleic acid molecule is targeted to a hematopoietic cell .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to a medicament , which has great effects of treating infectious swine streptococcosis , quickly clearing heat and detoxicating , cooling blood and eliminating dampness , eliminating vexation and engendering liquid , promoting recovery , and preventing secondary infection and other diseases .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The medicament has the advantages of exact curative effect , no residue , no toxic or side effects , high safety , and green environmentally-friendly preparation , and is favorable for healthy development of animal husbandry .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
A method of improving learning and/or memory behavior in a mammal is described which involves administering to the mammal casein glycomacropeptide in an amount sufficient to improve learning and/or memory behavior in the mammal .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention provides methods , uses and means for breast cancer prognostics and treatment prediction .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Provided methods comprises the steps of : providing a sample earlier obtained from a breast cancer subject ; evaluating the amount of ANLN protein present in at least part of said sample , and determining a sample value corresponding to said amount ; comparing the sample value with a reference value ; and , if said sample value is higher than said reference value , concluding that the subject is not likely to benefit from an endocrine treatment or that a prognosis for said subject is worse than a reference prognosis associated with the reference value .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Triazaspiro Compounds , compositions comprising a Triazaspiro Compound , methods for treating or preventing pain in an animal comprising administering to an animal in need thereof an effective amount of a Triazaspiro Compound and methods for stimulating opioid-receptor function in a cell comprising contacting a cell capable of expressing an opioid receptor with an effective amount of a Triazaspiro Compound are disclosed .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The inventions refers to a pharmaceutical composition and a preparation ( regime ) containing a hormone and a biocompatible zinc salt , as well as the use of a zinc salt and a contraceptive active hormone for the treatment of menstrual disorders , in particular to alleviate dysmenorrhea .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Compounds of formula ( I ) as well as pharmaceutically acceptable salts and esters thereof , wherein R1 to R5 , n , m and A have the significance given in claim 1 , can be used in the form of pharmaceutical preparations for the treatment or prevention of arthritis , cardiovascular diseases , diabetes , renal failure , eating disorders and obesity .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Disclosed is a 5-FU slow release injection comprising slow release microballoons and dissolvent , wherein the slow release microballoons include anti-cancer active constituent and slow release adjuvant , the dissolvent being common dissolvent or dissolvent containing suspending agent selected from sodium carboxymethylcellulose , mannitol , sorbitol , Tween-80 or their combination .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The anticancer active constituent being 5-FU and/or 5-FU synergistic agent selected from antimitotic drugs and/or alkyl agent , the slow release adjuvant being selected from polylactic acid , ethylene-vinyl acetate copolymer , Polifeprosan , FAD and sebacic acid copolymer , polyglycolic acid and glycollic acid copolymer or their combination .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention provides compositions comprising an inhibitor of dipeptidylpeptidase IV for modification and regulation of glucose and lipid metabolism , generally to reduce insulin resistance , hyperglycemia , hyperinsulinemia , obesity , hyperlipidemia , hyperlipoprotein-emia ( such as chylomicrons , VLDL and LDL ) , and to regulate body fat and more generally lipid stores , and , more generally , for the improvement of metabolism disorders , especially those associated with diabetes , obesity and/or atherosclerosis .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses an angustifolia lignans compound , a preparing method and application thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The compound has the right structural formula .
1 1 1 1 1 1 1 1 1 1 1 1
The method comprises the following steps of : drying and crushing the rattan of schisandra angustifolia , conducting ultrasonic extraction on crushed rattan in a fractionated way by using acetone ; merging and filtering extracting solution , concentrating the extracting solution into small volume in a decompression way , standing , filtering precipitates , extracting the filtered liquid for three times with ethyl acetate , and obtaining part extract liquid of the ethyl acetate , concentrating the liquid extract into an extractum , conducting chromatography and first fraction on the liquid extract with a silica gel column , then conducing further separation by adopting high-efficiency liquid phase semi-preparative chromatogram , thereby obtaining the required compound .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
anti-HIV-1 activity screening is conducted on the compound , and the experimental result demonstrates that the compound has good anti-HIV-1 activity and anti-oxidation activity , wherein HIV-1 therapeutic index is 22.5 , and anti-oxidation median elimination concentration IC50 is 8.22 mug/L .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Methods for rescuing learning , memory and/or motor function deficits associated with frontotemporal lobar degeneration with ubiquitinated inclusions ( FTLD-U ) are disclosed .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The method comprises : a ) administering to an animal having FTLD-U a therapeutically effective amount of an autophagy inducer ; b ) causing a decrease in the amount of ubiquitinated TDP-43 aggregation forms in the brain of the animal ; and c ) causing an improvement of the learning , memory capacities and/or motor function of the animal .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Methods and compositions for delivery of taxanes are disclosed .
1 1 1 1 1 1 1 1 1 1 1 1 1 1
Particularly disclosed are compositions of taxol solubilized in Vitamin E TPGS whereby the delivery of taxol is improved .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention relates to two lyophilized powder injections of methylprednisolone sodium succinate and preparation methods thereof .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Each lyophilized powder injection of methylprednisolone sodium succinate is obtained by dissolving 25.35-50.69mg of methylprednisolone succinate , 4.98-8.97mg of NaHCO3 , 1.60mg of NaH2PO4.H2O , and 17.4mg of Na2HPO4 in water for injection , adding water for injection until 1ml , filling , and lyophilizing .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention discloses a composition containing gatifloxacin , which comprises the following components in percentage by weight : 20-30 percent of glossy ganoderma , 10-25 percent of atifloxacin , 10-15 percent of liquorice , 5-20 percent of cordyceps sinensis , 10-20 percent of saururus chinensis , 10-20 percent of plantain and 5-15 percent of starch , wherein the total weight of various components is 100 percent .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The invention has the advantages of stable medicine property , remarkable therapeutic effect , quick response and low toxicity .
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
The present invention relates to novel compounds of formula ( I ) ' or a salt thereof : wherein G is selected from a group consisting of : phenyl , a 5- or 6-membered monocyclic heteroaryl group , or a 8- to 11 -membered heteroaryl bicyclic group ; A is a group P1 or a group P2 Wherein p is an integer ranging from 0 to 5 ; R1 is halogen , hydroxy , cyano , C1-4alkyl , haloC1-4alkyl , C1-4alkoxy , haloC1- 4alkoxy , C1-4alkanoyl and SF5 ; or corresponds to a group R6 ; and when p is an integer ranging from 2 to 5 , each R1 may be the same or different ; R2 is hydrogen or C1-4alkyl ; n is 3 , 4 , 5 or 6 ; R6 is a moiety selected from the group consisting of : isoxazolyl , -CH2-N-pyrrolyl , 1,1 -dioxido-2-isothiazolidinyl , thienyl , thiazolyl , pyridyl , 2-pyrrolidinonyl , and such R6 group is optionally substituted by one or two substituents selected from : halogen , cyano , C1- 4alkyl , haloC1-4alkyl , C1-4alkoxy , C1-4alkanoyl ; R4 is selected in the group consisting of : hydrogen , halogen , hydroxy , cyano , C1- 4alkyl , C3-7 cycloalkyl , haloC1-4alkyl , C1-4-alkoxy , haloC1-4alkoxy , C1-4alkanoyl and NR'R ' ; or R4 is a phenyl group , a 5-14 membered heterocyclic group ; and any of such phenyl or heterocyclic group is optionally substituted by 1 , 2 , 3 or 4 substituents selected from the group consisting of : halogen , cyano , C1-4alkyl , haloC1-4alkyl , C1-4alkoxy , C1-4alkanoyl , haloC1-4alkoxy and SF5 ; R5 is selected in the group consisting of : hydrogen , halogen , hydroxy , cyano , C1-4alkyl , C3-7 cycloalkyl , haloC1-4alkyl , C1-4alkoxy , haloC1-4alkoxy , C1-4alkanoyl and NR'R ' ; or R5 is a phenyl group , a 5-14 membered heterocyclic group ; and any of such phenyl or heterocyclic groups is optionally substituted by 1 , 2 , 3 or 4 substituents selected from the group consisting of : halogen , cyano , C1-4alkyl , haloC1-4alkyl , C1-4alkoxy , C1-4alkanoyl and SF5 ; R7 is hydrogen or C1-2alkyl ; R ' is H , C1-4 alkyl or C1-4 alkanoyl ; R ' is defined as R ' ; R ' and R ' taken together with the interconnecting nitrogen atom may form a 5- , 6- membered saturated or unsaturated heterocyclic ring ; wherein at least one of R4 and R5 is hydrogen ; and wherein only one R2 group may be different from hydrogen ; processes for their preparation , intermediates used in these processes , pharmaceutical compositions containing them and their use in therapy , as modulators of dopamine D3 receptors , e.g .
